News - Roche, Bristol-Myers Squibb

Filter

Current filters:

RocheBristol-Myers Squibb

Popular Filters

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Arrival of new hepatitis C therapies will increase the drug-treated population in China

Arrival of new hepatitis C therapies will increase the drug-treated population in China

19-06-2014

China’s market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated…

Anti-viralsasunaprevirBristol-Myers SquibbChinadanoprevirGilead SciencesJanssenMarkets & MarketingOlysioPharmaceuticalRocheSovaldi

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Modest growth seen for MAbs market for colorectal cancer, as late-stage pipeline is weak

14-12-2013

The market value for monoclonal antibodies in colorectal cancer treatment will experience a moderate…

AvastinBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck KGaAOncologyResearchRocheTakeda PharmaceuticalsVectibix

US patient share leaders in first-line BRAF-mutation positive malignant melanoma

27-11-2013

According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision…

Bristol-Myers SquibbGlaxoSmithKlineMarkets & MarketingMekinistNorth AmericaOncologyPharmaceuticalRocheTafinlarYervoyZelboraf

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline

30-09-2013

A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Oncologists positive on Tafinlar, Mekinist and nivolumab for unresectable malignant melanoma

11-07-2013

US and European oncologists surveyed by health care advisory firm Decision Resources indicate that overall…

BiotechnologyBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingMekinistnivolumabNorth AmericaOncologyPharmaceuticalRocheTafinlarZelboraf

New EULAR recommendations address use of synthetic and biological DMARDs

05-07-2013

The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Oncologists favor Avastin as first-line therapy for metastatic colorectal cancer

27-06-2013

For the treatment of metastatic colorectal cancer (mCRC), a majority of surveyed US oncologists surveyed…

AvastinBayerBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck SeronoNorth AmericaOncologyPharmaceuticalRegeneronRocheSanofiStivargaZaltrap

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments

01-11-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report

18-09-2012

The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

Yervoy and Zelboraf rapidly penetrating metastatic patient population in USA and Europe

23-08-2012

In the USA and Europe there is strong physician desire for new therapies for the treatment of early stage…

Bristol-Myers SquibbEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalRocheYervoyZelboraf

Amylin said to be attracting several Big Pharma suitors

16-05-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis

29-03-2012

There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis

25-11-2011

In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

Back to top